1-Ethyl-3-methyl-6-(2-propoxy-5-dimethylaminophenyl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-Ethyl-3-methyl-6-(2-propoxy-5-dimethylaminophenyl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one
• 英文别名: 6-(5-Dimethylamino-2-propoxy-phenyl)-1-ethyl-3-methyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one；6-[5-(dimethylamino)-2-propoxyphenyl]-1-ethyl-3-methyl-5H-pyrazolo[3,4-d]pyrimidin-4-one
• 化学式: C₁₉H₂₅N₅O₂
• 分子量: 355.44
• InChiKey: ALYKWZQKEAKZMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 1-Ethyl-3-methyl-6-(2-propoxy-5-aminophenyl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one 在 甲酸 作用下， 生成 1-Ethyl-3-methyl-6-(2-propoxy-5-dimethylaminophenyl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  一系列6-苯基吡唑并[3,4-d]嘧啶酮的合成及环GMP磷酸二酯酶的抑制活性。

  摘要：

  描述了一系列6-苯基吡唑并[3,4-d]嘧啶酮，它们是cGMP特异性（V型）磷酸二酯酶的特异性抑制剂。评价了酶和细胞活性以及体内口服降压活性。苯环的2位上的正丙氧基是活性所必需的。制备并评估了除2-正丙氧基外在5-位取代的一系列产物。这个职位可以容纳许多无关的团体。氨基衍生物非常有效，但缺乏代谢稳定性。碳连接的小杂环取代提供了高水平的活性和稳定性。细胞活性经常与体内活性相关。在这些化合物中，1,3-二甲基-6（2-丙氧基-5-甲磺酰胺基苯基）-1,5-二氢邻苯二酚[3，

  DOI：

  10.1021/jm950812j

文献信息

• Pyrazolopyrimidine Derivatives
  申请人：LABORATOIRES GLAXO SA

  公开号：EP0636626A1

  公开（公告）日：1995-02-01

  Pyrazolo[3,4-d]pyrimidin-4-one derivatives of formula (I) and salts and solvates thereof are described, in which: R¹ represents arylmethyl or C₁₋₆alkyl optionally substituted by one or more fluorine atoms; R² represents methyl; R³ represents C₂₋₄alkyl; R⁴ represents nitro, cyano, C₁₋₆alkoxy, C(=X)NR⁶R⁷, NR⁸R⁹, (CH₂)mNR¹⁰C(=Y)R¹¹ or a 5-membered heterocyclic ring selected from thienyl, thiazolyl and 1,2,4-triazolyl each ring optionally substituted by a C₁₋ ₄alkyl or aryl group; or when R¹ is arylmethyl or C₁₋₆alkyl substituted by one or more fluorine atoms then R⁴ may also represent hydrogen; R⁵ represents hydrogen or C₁₋₆alkyl; R⁶ represents hydrogen or C₁₋₆alkyl; R⁷ represents hydrogen, amino, hydroxyl, C₁₋₆alkyl, aryl or arylC₁₋₄alkyl; R⁸ represents hydrogen or C₁₋₆alkyl; R⁹ represents hydrogen, C₁₋₆alkyl, SO₂R¹², CO₂R¹², C(=NCN)SR¹² or C(=NCN)NR¹³R¹⁴; R¹⁰ represents hydrogen or C₁₋₆alkyl; R¹¹ represents C₁₋₆alkyl optionally substituted by one or more halogen atoms, or R¹¹ represents aryl, arylC₁₋₄alkyl, thienyl, NR¹⁵R¹⁶, CH₂NR¹⁷R¹⁸ or R¹⁰ and R¹¹ together represent -A(CH₂)n-; R¹² represents C₁₋₆alkyl, aryl or arylC₁₋₄alkyl; R¹³ represents hydrogen or C₁₋₆alkyl; R¹⁴ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl or R¹³ and R¹⁴ together with the nitrogen atom to which they are attached form a morpholine, piperazine or N-C₁₋₄alkylpiperazine ring; R¹⁵ represents hydrogen or C₁₋₆alkyl or R¹⁰ and R¹⁵ together represent -A(CH₂)n-; R¹⁶ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl, CO₂R¹², CH₂CO₂R¹² or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form a morpholine, piperazine or N-C₁₋₄alkylpiperazine ring; R¹⁷ represents hydrogen or C₁₋₆alkyl; R¹⁸ represents hydrogen, C₁₋₆alkyl, aryl, arylC₁₋₄alkyl, COR¹² or R¹⁷ and R¹⁸ together with the nitrogen atom to which they are attached form a morpholine, piperazine or N-C₁₋₄alkylpiperazine ring; A represents CH₂ or C=O; m represents zero or 1; n represents 1,2 or 3; X represents S or NH, or when R⁷ represents amino then X may also represent O; Y represents O or S; for use in therapy. These compounds are potent and selective inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase (cGMP specific PDE) and are useful in a variety of therapeutic areas, including the treatment of cardiovascular disorders.

  描述了式(I)的吡唑并[3,4-d]嘧啶-4-酮衍生物及其盐和溶剂化合物，其中：R¹代表芳基甲基或C₁₋₆烷基，可选择性地取代一个或多个氟原子；R²代表甲基；R³代表C₂₋₄烷基；R⁴代表硝基、氰基、C₁₋₆烷氧基、C(=X)NR⁶R⁷、NR⁸R⁹、(CH₂)mNR¹⁰C(=Y)R¹¹或选择自噻吩基、噻唑基和1,2,4-三唑基的5-成员杂环环，每个环可选择性地取代为C₁₋₄烷基或芳基；或当R¹为芳基甲基或C₁₋₆烷基取代一个或多个氟原子时，R⁴也可以代表氢；R⁵代表氢或C₁₋₆烷基；R⁶代表氢或C₁₋₆烷基；R⁷代表氢、氨基、羟基、C₁₋₆烷基、芳基或芳基C₁₋₄烷基；R⁸代表氢或C₁₋₆烷基；R⁹代表氢、C₁₋₆烷基、SO₂R¹²、CO₂R¹²、C(=NCN)SR¹²或C(=NCN)NR¹³R¹⁴；R¹⁰代表氢或C₁₋₆烷基；R¹¹代表C₁₋₆烷基，可选择性地取代一个或多个卤原子，或R¹¹代表芳基、芳基C₁₋₄烷基、噻吩基、NR¹⁵R¹⁶、CH₂NR¹⁷R¹⁸或R¹⁰和R¹¹一起代表-A(CH₂)n-；R¹²代表C₁₋₆烷基、芳基或芳基C₁₋₄烷基；R¹³代表氢或C₁₋₆烷基；R¹⁴代表氢、C₁₋₆烷基、芳基、芳基C₁₋₄烷基或R¹³和R¹⁴与它们连接的氮原子一起形成吗啡啉、哌嗪或N-C₁₋₄烷基哌嗪环；R¹⁵代表氢或C₁₋₆烷基或R¹⁰和R¹⁵一起代表-A(CH₂)n-；R¹⁶代表氢、C₁₋₆烷基、芳基、芳基C₁₋₄烷基、CO₂R¹²、CH₂CO₂R¹²或R¹⁵和R¹⁶与它们连接的氮原子一起形成吗啡啉、哌嗪或N-C₁₋₄烷基哌嗪环；R¹⁷代表氢或C₁₋₆烷基；R¹⁸代表氢、C₁₋₆烷基、芳基、芳基C₁₋₄烷基、COR¹²或R¹⁷和R¹⁸与它们连接的氮原子一起形成吗啡啉、哌嗪或N-C₁₋₄烷基哌嗪环；A代表CH₂或C=O；m代表零或1；n代表1,2或3；X代表S或NH，或当R⁷代表氨基时，X也可以代表O；Y代表O或S；用于治疗。这些化合物是环鸟苷3',5'-单磷酸特异性磷酸二酯酶（cGMP特异性PDE）的有效和选择性抑制剂，并在多种治疗领域中有用，包括治疗心血管疾病。